NCT02022917 - Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

January 31, 2021

Study Completion Date

January 31, 2021

Conditions

Epithelial Ovarian Cancer

Interventions

DRUG

Bevacizumab

Bevacizumab 15 mg/ Kg (from post-op cycle 2) intravenous infusion for 30 minutes in a 21 days' cycle for at least three cycles (best to 6 cycles) followed by 3-weekly maintenance bevacizumab 15 mg/ Kg intravenous infusion for 17 cycles.

Trial Locations (5)

Unknown

Department of Obstetrics & Gynecology, Chang Gung Memorial Hospital, Chiayi City

Department of Obstetrics & Gynecology Chang Gung Memorial Hospital, Kaohsiung City

China Medical University Hospital, Taichung

Wan Fang Hospital, Taipei Medical University,, Taipei

Division of Gynecologic Oncology, Department of Obstetrics & Gynecology Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan District

All Listed Sponsors

collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

Asian Gynecologic Oncology Group

OTHER

collaborator

Taiwanese Gynecolgic Oncology Group

UNKNOWN

lead

Chang Gung Memorial Hospital

OTHER